QNTM

TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court for the Southern District of New York has agreed to consolidate both the Company's direct action and a class action led by an individual investor alleging market manipulation. In addition, the court appointed experienced law firm Grant & Eisenhofer P.A. (“Grant & Eisenhofer”) as lead counsel in the class action. According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date in some of the most complex, often precedent-setting cases, in fights against the world's largest and richest opponents.

Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy Strategic collaboration with leading global contract research organization to implement randomized, double-blind, placebo-controlled Phase 2 study of novel neuroprotective therapy

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd.

Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces is pleased to announce its participation in the upcoming 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, taking place on September 16, 2026, at the Sheraton Center Toronto Hotel.

AUSTIN, Texas, Sept. 14, 2026 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” featuring Quantum BioPharma Ltd . (NASDAQ: QNTM).

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ: QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.